How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market
- By Drug Class: 5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Corticosteroids, Dopamine Antagonists, Cannabinoids
- By Route of Administration: Oral, Intravenous, Transdermal, Subcutaneous
- By Treatment Phase: Acute Phase CINV, Delayed Phase CINV, Anticipatory CINV
- By Patient Age Group: Pediatric, Adult, Geriatric
- By End User: Hospitals, Oncology Clinics, Ambulatory Care Centers, Home Care Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - 5-HT3 Receptor Antagonists leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Route of Administration 4
Treatment Phase 3
Patient Age Group 3
End User 4
Companies profiled
Roche Holding AG
Novartis AG
GlaxoSmithKline plc
Pfizer Inc.
AstraZeneca plc
Eli Lilly and Company
Helsinn Healthcare SA
Mitsubishi Tanabe Pharma Corporation
Heron Therapeutics Inc.
Sandoz (a Novartis division)
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Helsinn Healthcare SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Heron Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sandoz (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Teva Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sun Pharmaceutical Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Mylan N.V.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bristol-Myers Squibb Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,310M by 2033 · 8.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- 5-HT3 Receptor Antagonists49.2
- NK1 Receptor Antagonists12.0
- Corticosteroids14.5
- Dopamine Antagonists12.8
- Cannabinoids11.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,279M → $2,214M · 7.1%
Europe$891.2M → $1,583M · 7.4%
Asia Pacific$813.7M → $1,410M · 7.1%
Latin America$503.7M → $896.1M · 7.5%
Middle East and Africa$387.5M → $738.0M · 8.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.202026
8.222027
8.242028
8.242029
8.262030
8.272031
8.282032
8.302033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Holding AG11.7
- Novartis AG22.2
- GlaxoSmithKline plc12.1
- Pfizer Inc.11.1
- AstraZeneca plc10.2
- Eli Lilly and Company4.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class22.1%
Route of Administration13.0%
Treatment Phase15.4%
Patient Age Group29.2%
End User20.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.4
- Europe23.1
- Asia Pacific20.6
- Latin America13.1
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Holding AG | 77 | 96 | 92 | 84 | 87 | 76 | 85 |
| Novartis AG | 93 | 89 | 80 | 72 | 72 | 77 | 81 |
| GlaxoSmithKline plc | 76 | 87 | 79 | 71 | 70 | 67 | 75 |
| Pfizer Inc. | 61 | 61 | 64 | 82 | 75 | 63 | 68 |
| AstraZeneca plc | 60 | 60 | 53 | 55 | 72 | 68 | 61 |
| Eli Lilly and Company | 56 | 48 | 68 | 60 | 69 | 61 | 60 |
| Helsinn Healthcare SA | 62 | 55 | 66 | 62 | 61 | 41 | 58 |
| Mitsubishi Tanabe Pharma Corporation | 56 | 36 | 53 | 45 | 42 | 42 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Holding AG
- Novartis AG
- GlaxoSmithKline plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Holding AG | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Novartis AG | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| GlaxoSmithKline plc | − | ✓ | ✓ | ✓ | ◐ | ◐ |
| Pfizer Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| AstraZeneca plc | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Eli Lilly and Company | ◐ | − | − | − | ✓ | ✓ |
| Helsinn Healthcare SA | ◐ | − | − | ◐ | ◐ | − |
| Mitsubishi Tanabe Pharma Corporation | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Holding AG85
2Novartis AG81
3GlaxoSmithKline plc75
4Pfizer Inc.68
5AstraZeneca plc61
6Eli Lilly and Company60
7Helsinn Healthcare SA58
8Mitsubishi Tanabe Pharma Corporation46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Roche Holding AGNovartis AG
Challenger2
Strong scale, closing on the leaders.
GlaxoSmithKline plcPfizer Inc.
Contender3
Focused players with pockets of strength.
AstraZeneca plcEli Lilly and CompanyHelsinn Healthcare SA
Niche1
Specialists in a single segment or region.
Mitsubishi Tanabe Pharma Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market — a $98M beachhead inside a $1.47B market.
Beachhead (SOM)$98Mobtainable near-term
Serviceable (SAM)$531Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
5-HT3 Receptor Antagonists
Best fit — highest urgency & budget in Drug Class.
Economic buyer79 fit
NK1 Receptor Antagonists
Strong fit — clear ROI and a fast path to value.
End user69 fit
Corticosteroids
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Treatment Phase
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified21%
Evaluation13%
Closed-won7%
$21.0KCAC
$119KLTV
5.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market is a durable-growth opportunity — $8.93B by 2033, compounding at 6.5%.
TAM · 2025$5.40Btoday
TAM · 2033$8.93Bforecast
CAGR6.5%2027–2033
Cumulative$63.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.93BTotal addressable market
SAM$3.47BServiceable available market
SOM$650MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.5% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.93BLarge & growingTAM by 2033 at 6.5% CAGR
$3.47BServiceable nowreachable with today’s model
$650MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.97BBear4.2% CAGR
$8.93BBase6.5% CAGR
$11.4BBull8.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market — a $9.55B market by 2033. Plan: grow share from 10.6% to 17.6%.
Market size · 2033$9.55Btotal addressable
Market CAGR10.1%2027–2033
Target share17.6%from 10.6% today
Revenue ambition$1.68Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.6% | 17.6% | Ahead |
| Revenue | $939M | $1.68B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 36.0% | 45.9% | At risk |
| Customer retention | 87.7% | 96.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $180M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market conversation — a $2.35B market you can size, segment and defend in minutes.
Market size · 2033$2.35Btotal opportunity
Growth10.4%CAGR to 2033
Addressable buyers1,653+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 3 mopayback period
$84K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Roche Holding AGNovartis AGGlaxoSmithKline plcPfizer Inc.AstraZeneca plcEli Lilly and CompanyHelsinn Healthcare SAMitsubishi Tanabe Pharma Corporation+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Treatment Machines for External Beam Radiotherapy Market
Market size, share, segmentation and regional forecast.
$903M market · 2025 base year
View reportTreatment for Syndromes of Progressive Ataxia and Weakness Disorders Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportTreatment for Mental Health Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportTreatment for Gastroparesis Market
Market size, share, segmentation and regional forecast.
$583M market · 2025 base year
View reportTreatment Electrophysiology (EP) Catheter Market
Market size, share, segmentation and regional forecast.
$713M market · 2025 base year
View reportTreatment Devices for Hemorrhoid Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportTreatment Dental Equipment Market
Market size, share, segmentation and regional forecast.
$418M market · 2025 base year
View reportTreatment Couch Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportTreating Localized Stretch Marks Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportTrazodone Hydrochloride Tablets Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportTrazodone HCl Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportTray Cleaning Station Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.